Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603896.SS

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -58.39 M

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Capital Expenditure is USD -58.39 M for the year ending December 31, 2023, a -120.66% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -26.46 M, a -4.03% change year over year.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -25.44 M, a -155.52% change year over year.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -9.95 M, a 24.23% change year over year.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -13.14 M, a 61.20% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Shanghai Stock Exchange: 603896.SS

Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

CEO	Mr. Zhen-Yu Li
IPO Date	May 10, 2017
Location	China
Headquarters	No. 12, Huanglong Third Road
Employees	1,143
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale, crocus sativus, and other health products. The company was founded in 1997 and is based in Jinhua, China.

Key trends

Past 5 years